FI960979A0 - Förfarande för supression av humoral immunrespons - Google Patents

Förfarande för supression av humoral immunrespons

Info

Publication number
FI960979A0
FI960979A0 FI960979A FI960979A FI960979A0 FI 960979 A0 FI960979 A0 FI 960979A0 FI 960979 A FI960979 A FI 960979A FI 960979 A FI960979 A FI 960979A FI 960979 A0 FI960979 A0 FI 960979A0
Authority
FI
Finland
Prior art keywords
humoral immune
suppression
immune response
procedure
antagonist
Prior art date
Application number
FI960979A
Other languages
English (en)
Finnish (fi)
Other versions
FI960979A (sv
FI106927B (sv
Inventor
Randolph J Noelle
Teresa M Foy
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26813793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI960979(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of FI960979A0 publication Critical patent/FI960979A0/sv
Publication of FI960979A publication Critical patent/FI960979A/sv
Application granted granted Critical
Publication of FI106927B publication Critical patent/FI106927B/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
FI960979A 1993-09-02 1996-03-01 Förfarande för bestämning av huruvida en antigen är en TD-antigen eller en TI-2-antigen FI106927B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11599093A 1993-09-02 1993-09-02
US11599093 1993-09-02
US23292994 1994-04-25
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009872 WO1995006480A1 (en) 1993-09-02 1994-09-02 Methods of prolonged suppression of humoral immunity
US9409872 1994-09-02

Publications (3)

Publication Number Publication Date
FI960979A0 true FI960979A0 (sv) 1996-03-01
FI960979A FI960979A (sv) 1996-04-30
FI106927B FI106927B (sv) 2001-05-15

Family

ID=26813793

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960979A FI106927B (sv) 1993-09-02 1996-03-01 Förfarande för bestämning av huruvida en antigen är en TD-antigen eller en TI-2-antigen

Country Status (14)

Country Link
EP (1) EP0742721B1 (sv)
JP (1) JP2840131B2 (sv)
CN (1) CN1137726C (sv)
AT (1) ATE179616T1 (sv)
AU (3) AU7643094A (sv)
DE (1) DE69418349T2 (sv)
DK (1) DK0742721T3 (sv)
ES (1) ES2134954T3 (sv)
FI (1) FI106927B (sv)
GR (1) GR3030762T3 (sv)
IL (1) IL110852A (sv)
NO (1) NO321037B1 (sv)
NZ (1) NZ273208A (sv)
WO (1) WO1995006480A1 (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3308534B2 (ja) * 1991-10-25 2002-07-29 イミュネックス・コーポレーション 新規なサイトカイン
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
CA2089611A1 (en) * 1992-02-17 1993-08-18 Toshiro Yanase Antibacterial porous inorganic capsule and a process for producing the same

Also Published As

Publication number Publication date
FI960979A (sv) 1996-04-30
JP2840131B2 (ja) 1998-12-24
AU7643094A (en) 1995-03-22
ES2134954T3 (es) 1999-10-16
AU1422099A (en) 1999-04-01
DE69418349T2 (de) 1999-09-09
NO960863L (no) 1996-04-30
GR3030762T3 (en) 1999-11-30
NZ273208A (en) 2000-12-22
DE69418349D1 (de) 1999-06-10
FI106927B (sv) 2001-05-15
AU2004240180A1 (en) 2005-01-27
WO1995006480A1 (en) 1995-03-09
IL110852A (en) 1999-05-09
CN1137758A (zh) 1996-12-11
EP0742721B1 (en) 1999-05-06
NO960863D0 (no) 1996-03-01
NO321037B1 (no) 2006-03-06
ATE179616T1 (de) 1999-05-15
EP0742721A1 (en) 1996-11-20
JPH09502184A (ja) 1997-03-04
IL110852A0 (en) 1994-11-28
CN1137726C (zh) 2004-02-11
AU734853B2 (en) 2001-06-21
AU2004240180B2 (en) 2007-08-09
DK0742721T3 (da) 1999-11-01

Similar Documents

Publication Publication Date Title
FI960979A (sv) Förfarande för supression av humoral immunrespons
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
EP0863913A4 (en) METHOD FOR RECOVERING THE DENSITY OF ANTIGENS ON ANTIGENT PRESENTING CELLS
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
FI940335A0 (sv) Inducering av cytotoxiska T-lymfocytresponser
GB9818627D0 (en) Improvements in dva vaccination
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
AU709406C (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
PT991403E (pt) Uso de microparticulas com antigenio adsorvido para estimular respostas imunes
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
TR200101055T2 (tr) Adjuvan sistemler ve aşılar
TR200001706T2 (tr) Fosfodiester IV inhibisyonuna sahip purin türevleri
HU9401109D0 (en) Recombitope peptides
ATE364048T1 (de) Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
DK0882132T3 (da) Et kombineret humant cytomegalovirus-antigen og anvendelse heraf
PT1021196E (pt) Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio
Krakauer Evidence for protein kinase C pathway in the response of human peripheral blood mononuclear cells to cholera toxin
FI923020A (fi) Inte a inte b-sekvenser.
DK41885A (da) 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen
EP0293333A3 (en) A synthetic nonapeptide of use as an adjuvant
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
BR9713959A (pt) Uso de material antigênico e/ou imunorregulatório derivado da mycobacterium vaccae, composição compreedendo o mesmo, e, processo para regulação descendente da atividade th2 do sistema imunológico de um indivìduo
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse